• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals Inc

    5/13/26 10:53:16 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    LB PHARMACEUTICALS INC

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)




    50180M108

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    50180M108


    1Names of Reporting Persons

    JPMORGAN CHASE & CO
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,311,423.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,427,568.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,427,568.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LB PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    One Pennsylvania Plaza, Suite 1025, NEW YORK, NEW YORK, 10119.
    Item 2. 
    (a)Name of person filing:

    JPMORGAN CHASE & CO
    (b)Address or principal business office or, if none, residence:

    270 Park Avenue, New York, NY 10017
    (c)Citizenship:

    DE
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    50180M108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,427,568
    (b)Percent of class:

    4.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,311,423

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,427,568

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JPMORGAN CHASE & CO
     
    Signature:Rachel Tsvaygoft
    Name/Title:Vice President
    Date:05/13/2026
    Get the next $LBRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LBRX

    DatePrice TargetRatingAnalyst
    4/27/2026$45.00Buy
    H.C. Wainwright
    4/10/2026$36.00Buy
    Craig Hallum
    1/9/2026Buy
    Roth Capital
    10/6/2025$27.00Buy
    Stifel
    10/6/2025$78.00Overweight
    Piper Sandler
    10/6/2025$34.00Outperform
    Leerink Partners
    More analyst ratings

    $LBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on LB Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $45.00

    4/27/26 8:36:32 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on LB Pharmaceuticals with a new price target

    Craig Hallum initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $36.00

    4/10/26 8:41:05 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on LB Pharmaceuticals

    Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy

    1/9/26 9:05:22 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LB Pharmaceuticals to Participate in Upcoming June Investor Events

    NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 2:35 p.m. ET H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Date: Tuesday, June 16, 2026 Time: Presentation available on the LB Pharmaceuticals w

    5/28/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

    Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression  Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -

    5/12/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

    Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled "Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizo

    4/22/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Deep Track Biotechnology Master Fund, Ltd. converted options into 686,138 shares and bought $39,999,990 worth of shares (2,666,666 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 6:09:13 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussbaum Ran converted options into 411,681 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:05 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Pontifax Management 4 G.P. (2015) Ltd. bought $15,000,000 worth of shares (1,000,000 units at $15.00) and converted options into 411,681 shares (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:07 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals Inc

    SCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)

    5/13/26 10:53:16 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by LB Pharmaceuticals Inc

    424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)

    5/12/26 5:15:29 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by LB Pharmaceuticals Inc

    10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)

    5/12/26 4:31:19 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ruffolo Robert R

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    6/5/26 6:04:35 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nussbaum Ran

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    6/5/26 5:35:07 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Luse Rebecca

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    6/5/26 5:32:20 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Leadership Updates

    Live Leadership Updates

    View All

    LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

    Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression  Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -

    5/12/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals

    3/9/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg

    1/21/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care